ライフサイエンスコーパス: monkeypox

1 s with confirmed and probable cases of human monkeypox.

2 , and outline the laboratory confirmation of monkeypox.

3 ho was initially suspected of infection with monkeypox.

4 eaks of emerging infectious diseases such as monkeypox.

5 ivo kinetics of T-cell responses in smallpox/monkeypox.

6 ne responses and vaccine-induced immunity to monkeypox.

7 Of 3 family members with monkeypox, 2 had rash illness only, and 1 required hospi

8 immunologically most similar to smallpox is monkeypox, a zoonosis endemic to moist forested regions

9 Our analysis of monkeypox also clarifies the various ways that imperfect

10 promised the Dryvax-induced immunity against monkeypox, although the covaccinated monkeys exhibited m

11 a bioweapon and the emerging threat of human monkeypox, among other poxviral diseases, highlight the

12 ariola, the causative agent of smallpox, and monkeypox, an emerging virus of great concern for human

13 such as human immunodeficiency virus (HIV), monkeypox and severe acute respiratory syndrome (SARS) w

14 gens, which includes the causative agents of monkeypox and smallpox.

15 pler, safer, and more effective vaccines for monkeypox and smallpox.

16 hat includes the human pathogens variola and monkeypox and the vaccine species vaccinia virus.

17 activity against orthopox viruses (smallpox, monkeypox, and cowpox virus) of the synthesized nucleosi

18 hemagglutinin (HA) gene in camelpox, cowpox, monkeypox, and vaccinia viruses.

19 Neutralization titers to vaccinia, monkeypox, and variola major were assessed and cell-medi

20 to multiple poxviruses, including vaccinia, monkeypox, and variola major, and broad T-cell responses

21 ected in the throat, tonsil, and spleen, and monkeypox antigen was detected in the lung, hilar and su

22 virus (VACV), protects against smallpox and monkeypox, but is contraindicated in immunocompromised i

23 ultiple orthopoxviruses, including vaccinia, monkeypox, camelpox, cowpox, ectromelia (mousepox), and

24 poxviruses (OPV): variola, vaccinia, cowpox, monkeypox, camelpox, ectromelia, and taterapox viruses.

25 entification and differentiation of variola, monkeypox, camelpox, vaccinia, and cowpox virus species

26 tive antiviral immunity against West African monkeypox can potentially be maintained for decades afte

27 ovember 2007, 760 laboratory-confirmed human monkeypox cases were identified in participating health

28 d offers protection from a highly pathogenic monkeypox challenge.

29 keys exhibited measurable protection against monkeypox compared to that of naive controls.

30 es, and most mammalian poxviruses, including monkeypox, cowpox, and ectromelia.

31 on-Variola orthopoxvirus isolates, including monkeypox, cowpox, and vaccinia viruses, for rapid detec

32 s variola major virus, camelpox, buffalopox, monkeypox, cowpox, and variola minor viruses.

33 As demonstrated for monkeypox data from the Democratic Republic of Congo, th

34 ng recent outbreaks of cutaneous anthrax and monkeypox demonstrate the importance of dermatologist pr

35 lustrate a spectrum of clinical illness with monkeypox despite a common source of exposure; manifesta

36 [(18)F]-fluorodeoxyglucose (FDG) can monitor monkeypox disease progression in vivo in nonhuman primat

37 activation that may allow risk assessment of monkeypox disease.

38 alyzed human monkeypox incidence trends in a monkeypox-enzootic region.

39 whether caused by escape of viruses such as monkeypox from indigenous areas or intentional release o

40 Available small animal models of human monkeypox have been restricted to mammals with poorly de

41 fer hope for the treatment and prevention of monkeypox; however, more research must be done before th

42 dicate that route of infection can influence monkeypox illness manifestations.

43 that a subunit vaccine approach to smallpox-monkeypox immunization is feasible.

44 We describe a cluster of monkeypox in a family with a spectrum of clinical illnes

45 In addition, sporadic outbreaks of human monkeypox in Africa and a recent outbreak of human monke

46 ntified three previously unreported cases of monkeypox in preimmune individuals at 13, 29 and 48 year

47 The recent observation of a surge in human monkeypox in the Democratic Republic of the Congo (DRC)

48 Studies on the burden of human monkeypox in the Democratic Republic of the Congo (DRC)

49 The outbreak of monkeypox in the Midwestern United States during June 20

50 pox in Africa and a recent outbreak of human monkeypox in the U.S. have made it clear that naturally

51 e virus, and the discovery of human cases of monkeypox in the United States.

52 The outbreak of monkeypox in the Unites States in the summer of 2003 was

53 We report that monkeypox, in addition to causing febrile rash illness,

54 smallpox vaccination campaigns ceased, human monkeypox incidence has dramatically increased in rural

55 current risk of infection, we analyzed human monkeypox incidence trends in a monkeypox-enzootic regio

56 10,000) suggests a 20-fold increase in human monkeypox incidence.

57 the early pathogenic events of inhalational monkeypox infection in NHPs were characterized, and the

58 resent study, the early pathogenic events of monkeypox infection in nonhuman primates, a surrogate fo

59 events occurring in an inhalational macaque monkeypox infection model, supporting its use as a surro

60 Previously, the later stages of monkeypox infection were defined, but the early course o

61 d >or=90% specificity for detecting clinical monkeypox infection, we identified three previously unre

62 the degree of age-specific immunity against monkeypox, influenza A(H5N1) and A(H7N9), and refined ex

63 The monkeypox inhibitor of complement enzymes (MOPICE), whic

64 d a virulence factor expressed by monkeypox (monkeypox inhibitor of complement enzymes or MOPICE).

65 cines protect healthy macaques from a lethal monkeypox intravenous challenge, our data identify LC16m

66 Human monkeypox is a zoonotic Orthopoxvirus with a presentatio

67 n fatalities, this outbreak illustrates that monkeypox is an emerging natural infection and a potenti

68 in orthopoxvirus infection.IMPORTANCE Human monkeypox is an emerging zoonotic infectious disease cau

69 Human monkeypox is an endemic disease in rain-forested regions

70 Human monkeypox is considered an emerging zoonotic infectious

71 Monkeypox is endemic in regions of western and central A

72 lement inhibitors of smallpox, vaccinia, and monkeypox known as SPICE, VCP (or VICE), and MOPICE, res

73 accine to protect people against smallpox, a monkeypox model of infection in cynomolgus macaques, whi

74 haracterized a virulence factor expressed by monkeypox (monkeypox inhibitor of complement enzymes or

75 and projected future distributions of human monkeypox (MPX).

76 Monkeypox (MPXV) and cowpox (CPXV) are emerging agents t

77 lpox, cowpox, ectromelia, gerbilpox, herpes, monkeypox, myxoma, rabbitpox, raccoonpox, skunkpox, vacc

78 engendered during eradication efforts, could monkeypox now gain a foothold in human communities?

79 In April 2003, an outbreak of monkeypox occurred in the United States following the im

80 hesus macaques with plasmid DNA encoding the monkeypox orthologs of the VACV L1R, A27L, A33R, and B5R

81 smallpox-based bioterrorist event or a human monkeypox outbreak has heightened the importance of new,

82 The US monkeypox outbreak of 2003 provided the opportunity to e

83 Together, this shows that the US monkeypox outbreak was larger than previously realized a

84 accinia strains being tested for variola and monkeypox prevention and for the delivery of heterologou

85 s ago; orthopox viruses such as smallpox and monkeypox remain serious public health threats both thro

86 other related pathogenic poxviruses, such as monkeypox, remain potential bioterrorist weapons or coul

87 oxvirus infection, such as human smallpox or monkeypox, remain to be fully identified.

88 epidemiologic limitations that could impede monkeypox's emergence as a significant pathogen of human

89 The virus was identified by detection of monkeypox-specific DNA sequences in tissues or isolates

90 cinated persons had a 5.2-fold lower risk of monkeypox than unvaccinated persons (0.78 vs. 4.05 per 1

91 x viruses, as well as those such as variola, monkeypox, vaccinia, and camelpox viruses, which do not.

92 omolgus macaques were exposed to aerosolized monkeypox virus (10(5) PFU).

93 reexpansion in association with sterile anti-monkeypox virus (anti-MPV) immunity after MPV challenge.

94 Monkeypox virus (MPV) is a virulent human pathogen that

95 monstrate that the Poxviridae family members monkeypox virus (MPX) and variola virus (VarV) use conse

96 Infection with monkeypox virus (MPXV) causes disease manifestations in

97 While the monkeypox virus (MPXV) genome encodes a homologue of the

98 Monkeypox virus (MPXV) infection has recently expanded i

99 Monkeypox virus (MPXV) is a human pathogen that is a mem

100 Monkeypox virus (MPXV) is an orthopoxvirus closely relat

101 Monkeypox virus (MPXV) is an orthopoxvirus closely relat

102 Infection of nonhuman primates (NHPs) with monkeypox virus (MPXV) is currently being developed as a

103 Monkeypox virus (MPXV) is endemic in Africa, where it ca

104 Monkeypox virus (MPXV) is endemic within Africa where it

105 The 2003 monkeypox virus (MPXV) outbreak and subsequent laborator

106 To better understand the occurrence of monkeypox virus (MPXV), an emerging Orthopoxvirus in hum

107 e United States following the importation of monkeypox virus (MPXV)-infected animals in a consignment

108 erging zoonotic infectious disease caused by Monkeypox virus (MPXV).

109 elting temperature [T(m)], 56.40 degrees C), monkeypox virus (T(m), 56.24 degrees C), and vaccinia vi

110 (m)s, 61.7 to 62.7 degrees C), 15 strains of monkeypox virus (T(m)s, 61.9 to 62.2 degrees C), 40 stra

111 causative agent of smallpox, and the related monkeypox virus are both select agents that, if purposef

112 The prairie dog, using monkeypox virus as a challenge virus, has provided a val

113 macaques were challenged intravenously with monkeypox virus at 4, 6, 10, and 30 days after immunizat

114 e macaques were not protected against lethal monkeypox virus challenge if their CD4(+) cell count was

115 th MVA provided protection for >2 years in a monkeypox virus challenge model.

116 us compound ST-246 in prairie dogs against a monkeypox virus challenge of 65 times the 50% lethal dos

117 Recent monkeypox virus challenge studies have established the b

118 could be boosted as a recall response after monkeypox virus challenge.

119 odeoxyglucose ([(18)F]-FDG) in monkeys after monkeypox virus exposure to monitor the immune response

120 ocuments the isolation and identification of monkeypox virus from humans in the Western Hemisphere.

121 ain reaction and culture revealed infectious monkeypox virus in skin lesions of all 3 patients; 2 pat

122 ed a valuable nonhuman animal model in which monkeypox virus infection closely resembles human system

123 Monkeypox virus infection of nonhuman primates (NHPs) pr

124 Monkeypox virus infection results in a systemic, febrile

125 One year after monkeypox virus infection, 6 of 7 individuals had IFN- g

126 ted with VV, 7 individuals with a history of monkeypox virus infection, and 8 individuals with a hist

127 Understanding the mechanisms of monkeypox virus innate immune evasion will help us to un

128 Subsequent monkeypox virus intranasal infection of vaccinated prair

129 Monkeypox virus is a less efficient human pathogen than

130 Monkeypox virus is an emerging, zoonotic orthopoxvirus w

131 uses smallpox) is the most pathogenic, while monkeypox virus is intermediate in pathogenicity between

132 Monkeypox virus was recovered in cell cultures of seven

133 enetic constrains are sufficient to diminish monkeypox virus' capacity for enhanced specificity as a

134 revented spread of vaccinia virus as well as monkeypox virus, a human pathogen.

135 re essential for protection of macaques from monkeypox virus, a variola virus ortholog.

136 thogenic orthopoxviruses like variola virus, monkeypox virus, and cowpox virus (CPXV), but not vaccin

137 (HSV-2), human immunodeficiency virus (HIV), monkeypox virus, and hepatitis B virus.

138 accinia virus, the emerging infectious agent monkeypox virus, and the potential biothreat variola vir

139 ception, exhibiting extreme vulnerability to monkeypox virus, cowpox virus, and vaccinia virus and th

140 nt of smallpox (variola virus), the zoonotic monkeypox virus, the vaccine and zoonotic species vaccin

141 After challenge with monkeypox virus, unimmunized animals developed more than

142 ion from a lethal intravenous challenge with monkeypox virus.

143 a, vaccinia, camelpox, mousepox, cowpox, and monkeypox virus.

144 d new and emerging infectious agents such as monkeypox virus.

145 ase after an otherwise lethal challenge with monkeypox virus.

146 une regime (69 U/ml) prior to challenge with monkeypox virus.

147 Cowpox and monkeypox viruses have taken an alternate approach by en

148 protein (OMCP) is conserved among cowpox and monkeypox viruses, secreted by infected cells, and bound

149 uring human infections with the smallpox and monkeypox viruses, which are highly homologous to ectrom

150 % identity in all orthopoxviruses except for monkeypox viruses, whose O3 homologs have 2 to 3 amino a

151 Monkeypox, with associated encephalitis, occurred in the

152 us agents, such smallpox or a related virus, monkeypox, would have catastrophic consequences.